Suppr超能文献

监测复发性丙型肝炎外周血 CD4+三磷酸腺苷活性及其与纤维化进展的相关性。

Monitoring peripheral blood CD4+ adenosine triphosphate activity in recurrent hepatitis C and its correlation to fibrosis progression.

机构信息

Department of Pediatric Gastroenterology, Cleveland Clinic, Cleveland, OH 44195, USA.

出版信息

Liver Transpl. 2010 Feb;16(2):155-62. doi: 10.1002/lt.21939.

Abstract

The recurrence of hepatitis C virus (HCV) after orthotopic liver transplantation (OLT) is often associated with rapid fibrosis progression attributed to the state of impaired cellular immunity. At present, there are no means to predict those at risk for progression. Peripheral blood CD4+ adenosine triphosphate (ATP) release (the ImmuKnow assay) correlates with immunoreactivity and has been used to monitor global cellular immune function in transplant recipients. The aim of this study was to assess the relationship between cellular immune function measured by the ImmuKnow assay and fibrosis progression in patients with HCV recurrence after OLT. The ImmuKnow assay was prospectively performed in adult HCV patients at 4 and 12 months post-OLT. Protocol liver biopsies were performed (on day 7, in month 4, and yearly) after OLT. The first biopsy that showed fibrosis post-OLT was used to determine the time interval for developing fibrosis. Sixty-two patients met the inclusion criteria. The median follow-up time was 12 (6.5-12.1) months. Fibrosis progression was observed in 61.3% of the patients. ATP levels were lower in patients with fibrosis progression in comparison with patients without progression at 4 months (145 versus 259 ng/mL, P < 0.001) and at 12 months (152 versus 264 ng/mL, P = 0.008). ATP levels at 4 and 12 months post-OLT were found to be significantly associated with a higher hazard of progression. For each 25-unit increase in ATP levels at 4 and 12 months after transplantation, the hazard of fibrosis progression decreased by 22% (P = 0.001) and 12% (P = 0.015), respectively. In conclusion, greater suppression of cellular immunity, as measured by the ImmuKnow assay, is associated with more rapid progression of fibrosis in patients with recurrent HCV post-OLT. Post-OLT monitoring of CD4+ ATP activity may identify a subset of patients at greatest risk for early fibrosis progression.

摘要

肝移植(OLT)后丙型肝炎病毒(HCV)的复发常伴有细胞免疫受损导致的快速纤维化进展。目前,尚无预测进展风险的方法。外周血 CD4+三磷酸腺苷(ATP)释放(ImmuKnow 测定)与免疫反应相关,已用于监测移植受者的整体细胞免疫功能。本研究旨在评估 ImmuKnow 测定法测量的细胞免疫功能与 OLT 后 HCV 复发患者纤维化进展之间的关系。在 OLT 后 4 个月和 12 个月对 HCV 患者进行了前瞻性的 ImmuKnow 检测。OLT 后进行了方案性肝活检(第 7 天、第 4 个月和每年)。OLT 后首次显示纤维化的活检用于确定发生纤维化的时间间隔。62 例患者符合纳入标准。中位随访时间为 12(6.5-12.1)个月。61.3%的患者发生纤维化进展。与无进展患者相比,纤维化进展患者在 4 个月(145 与 259 ng/mL,P < 0.001)和 12 个月(152 与 264 ng/mL,P = 0.008)时 ATP 水平更低。OLT 后 4 个月和 12 个月的 ATP 水平与更高的进展风险显著相关。移植后 4 个月和 12 个月时,ATP 水平每增加 25 个单位,纤维化进展的风险就会降低 22%(P = 0.001)和 12%(P = 0.015)。总之,ImmuKnow 测定法测量的细胞免疫抑制程度越大,OLT 后复发性 HCV 患者的纤维化进展速度越快。OLT 后 CD4+ATP 活性监测可能会识别出具有早期纤维化进展高风险的患者亚组。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验